DK0488061T3 - MAC-1-bindingsposition for ICAM-1 - Google Patents

MAC-1-bindingsposition for ICAM-1

Info

Publication number
DK0488061T3
DK0488061T3 DK91119894T DK91119894T DK0488061T3 DK 0488061 T3 DK0488061 T3 DK 0488061T3 DK 91119894 T DK91119894 T DK 91119894T DK 91119894 T DK91119894 T DK 91119894T DK 0488061 T3 DK0488061 T3 DK 0488061T3
Authority
DK
Denmark
Prior art keywords
icam
mac
binding position
relates
molecules
Prior art date
Application number
DK91119894T
Other languages
Danish (da)
English (en)
Inventor
Donald E Staunton
Michael S Diamond
Timothy A Springer
Original Assignee
Blood Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blood Res Center filed Critical Blood Res Center
Application granted granted Critical
Publication of DK0488061T3 publication Critical patent/DK0488061T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ropes Or Cables (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Package Frames And Binding Bands (AREA)
  • Hall/Mr Elements (AREA)
DK91119894T 1990-11-28 1991-11-21 MAC-1-bindingsposition for ICAM-1 DK0488061T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/618,286 US5288854A (en) 1990-11-28 1990-11-28 Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1

Publications (1)

Publication Number Publication Date
DK0488061T3 true DK0488061T3 (da) 1999-07-19

Family

ID=24477094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91119894T DK0488061T3 (da) 1990-11-28 1991-11-21 MAC-1-bindingsposition for ICAM-1

Country Status (8)

Country Link
US (1) US5288854A (fr)
EP (1) EP0488061B1 (fr)
KR (1) KR920009412A (fr)
AT (1) ATE172988T1 (fr)
DE (1) DE69130445T2 (fr)
DK (1) DK0488061T3 (fr)
ES (1) ES2122964T3 (fr)
NZ (2) NZ240747A (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
ES2134762T3 (es) * 1990-07-20 1999-10-16 Bayer Ag Formas multimericas de proteinas receptoras de rinovirus humanos.
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
AU674556B2 (en) * 1992-10-09 1997-01-02 Center For Blood Research, Inc., The A subpopulation of MAC-1 molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
ATE448306T1 (de) * 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
WO2002059114A1 (fr) * 2000-11-28 2002-08-01 Genentech, Inc. Composes antagonistes lfa-1
CA2544678C (fr) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulateurs de l'adhesion cellulaire
EP1789447B1 (fr) * 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Méthode d'interférence arn et utilisations
US20060233675A1 (en) * 2005-04-13 2006-10-19 Stein Israel M Glass test tube having protective outer shield
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
WO2007127272A2 (fr) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Méthode de production d'immunoliposomes et compositions les incluant
EP2018436A2 (fr) * 2006-04-25 2009-01-28 Immune Disease Institute Inc. Administration ciblée vers des leucocytes au moyen de supports non protéiniques
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
WO2009128932A1 (fr) * 2008-04-15 2009-10-22 Sarcode Corporation Administration d'antagonistes de lfa-1 au système gastro-intestinal
WO2009128934A1 (fr) * 2008-04-15 2009-10-22 Sarcode Corporation Antagonistes de lfa-1 topiques utilisés dans le traitement localisé de troubles de nature immunitaire
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
KR20200108932A (ko) 2012-07-25 2020-09-21 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
EP3897851A2 (fr) 2018-12-17 2021-10-27 Revitope Limited Recruteur de cellules immunitaires jumelles
CA3202045A1 (fr) 2020-12-18 2022-06-23 Scheyla KUESTER Procede de fabrication de composite electriquement conducteur

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ES2201052T3 (es) * 1988-09-28 2004-03-16 Dana Farber Cancer Institute Moleculas de adhesion intercelular y sus ligandos de union.

Also Published As

Publication number Publication date
ATE172988T1 (de) 1998-11-15
US5288854A (en) 1994-02-22
EP0488061B1 (fr) 1998-11-04
KR920009412A (ko) 1992-06-25
ES2122964T3 (es) 1999-01-01
EP0488061A2 (fr) 1992-06-03
NZ260473A (en) 1997-06-24
NZ240747A (en) 1996-05-28
EP0488061A3 (en) 1992-08-26
DE69130445D1 (de) 1998-12-10
DE69130445T2 (de) 1999-07-08

Similar Documents

Publication Publication Date Title
DK0488061T3 (da) MAC-1-bindingsposition for ICAM-1
DK0445255T4 (da) Anvendelse af hyaluronsyre i kombination med ascorbinsyre, antitumormidler og/eller NSAID's til behandling af cancer
EP0730609A4 (fr) Anticorps recombines contre l'il4 utiles dans le traitement des affections induites par l'il4
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
GR3006073T3 (fr)
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
EP0528931A4 (en) Humanized chimeric anti-icam-1 antibodies, methods of preparation and use
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
DK0513702T3 (da) Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering
IL115733A0 (en) Binding agents and their use for therapeutic treatment
FI923911A7 (fi) DNA-molekyylien in vitro-synteesi
IT1241984B (it) Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
DE3889974D1 (de) Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.
FI911788A7 (fi) Difluoriglutamiinihapon konjugaatteja folaattien ja antifolaattien kanssa uudiskasvusairauksien hoitoa varten
FI924475A7 (fi) Trinitrobentseenien tai karmiinihapon käyttö syövän ja virusperäisten sairauksien hoidossa
FI911778A7 (fi) Difluoriglutamiinihappo-konjugaatit folaattien ja antifolaattien kanssa neoplastisten sairauksien hoitoon
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
DK468885D0 (da) Middel til topisk behandling af betaendelsestilstande i huden
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
FI971879L (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
ATE315583T1 (de) Analoge des thymosin alpha 1
ATE79759T1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ITMI941036A0 (it) Impiego dell'epilattosio nel trattamento dei tumori e delle malattie autoimmuni